期刊文献+

菌种筛选对1型肺炎链球菌产糖量的影响

Effect of bacterial colony screening on polysaccharide yield of Streptococcus pneumoniae serotype 1
原文传递
导出
摘要 目的用无动物源性培养基筛选高产糖1型肺炎链球菌(Streptococcus pneumoniae semtype1,PN1)。方法配制无动物源性培养基,并用此培养基进行高产糖PN1单菌落筛选。比较筛选前后PN1在发酵培养中的产糖量。结果无动物源性培养基筛选前后PN1在发酵培养中的产糖量分别为420和960mg/L,筛选后PN1的产糖量明显高于筛选前PN1。结论以无动物源性培养基筛选PNI可使PN1的产糖量明显提高。 Objective To screen a colony of Streptococcus pneumoniae serotype 1 (PN1) with high polysaccharide yield using animal-free medium. Methods The animal-free medium was prepared and used to screen a single colony of PN1 with high polysaceharide yield. The polysaecharide yield of PN1 in fermentation culture was compared between before and after screening. Results The polysaccharide yields of PN1 before and after screening with the animal-free medium were 420 and 960 mg/L in fermen- tation culture, respectively. The polysaccharide yield of PN1 was significantly higher after screening than before screening. Conclusion PN1 screening with animal-free medium can significantly increase polysaccharide yield of PN1.
出处 《国际生物制品学杂志》 CAS 2014年第3期126-128,136,共4页 International Journal of Biologicals
基金 国家国际科技合作项目(2012DF33450)
关键词 链球菌 肺炎 多糖类 细菌 培养基 菌种筛选 Streptococcus pneumoniae Polysaccharides, bacterial Culture media Bacterial colony screening
  • 相关文献

参考文献12

  • 1Lee CJ, Banks SD, Li JP. Virulence, immunity, and vaccine related to Streptococcus pneumoniae [J]. Crit Rev Microbiol, 1991, 18(2): B9-114.
  • 2Liberman C, Takagi M, Cabrera-Crespo J, et al. Pneumococcal whole-cell vaccine: optimization of cell growth of uneneapsu lated Streptococcus pneumoniae in bioreaetor using animal-{ree medium [J]. J Ind Mierobiol Biotechnol, 2008, 35(11 ) : 1441- 1445.
  • 3王剑虹(综述),江丽君(审校).肺炎链球菌疫苗研究进展[J].国际生物制品学杂志,2012,35(1):37-40. 被引量:8
  • 4Reijtman V, Fossati S, Hernandea C, et al. Serotype distribu- tion of pneumococci isolated from pediatric patients with acute otitis media and invasive infections, and potential coverage of pneumocoecal conjugated vaccines [J]. Rev Argent Microbiol, 2013, 45(1): 27-33.
  • 5Hoeprich PD. CTM labelling of Diplococcus pneumoniae[J]. J Bacteriol, 1955, 69(6): 682-688.
  • 6刘威,廖红梅,姚静,江山,崔长法.1型肺炎球菌多糖竞争ELISA检测方法的建立[J].中国新药杂志,2012,21(10):1123-1126. 被引量:6
  • 7World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines [EB/OL]. (2010-04-23) [2013-12 08]. http://www, who. int/biologicals/areas/vacdnes/pneumo/Pneumo_final 23 APRIL_ 2010. pdf.
  • 8Esposito S, Tansey S, Thompson A, et al. Safety and immuno- genicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneurnococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers [J]. Clin Vaccine Immunol, 2010, 17(6) : 1017-1026.
  • 9Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conju-gate vaccine given with routine pediatric vaccinations in Ger many [J]. Vaccine, 2010, 28(25): 4192-4203.
  • 10Gone alves VM, Zangirolami TC, Giordano RL, et al. Opti- mization of medium and cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae sero- type 23F [J]. Appl Microbiol Biotechnol, 2002, 59(6): 713- 717.

二级参考文献39

  • 1于兹东,杨桂明,高华,刘坤.咔唑分光光度法测定硫酸软骨素[J].青岛大学学报(自然科学版),2005,18(3):41-44. 被引量:13
  • 2Whitney CG,Pilishvili T,Farley MM,et al.Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease:a matched case-control study[J].Lancet,2006,368(9546):1459-1502.
  • 3Dinleyici EC,Yargic ZA.Pneumococcal conjugated vaccines:impact of PCV-7 and new achievements in the postvaccine era[J].Expert Rev Vaccines,2008,7(9):1367-1394.
  • 4Feavers I,Knezevic I,Powell M,et al.Challenges in the evaluation and licensing of new pneumococcal vaccines,7-8 July2008,Ottawa,Canada[J].Vaccine,2009,27 (28):3681-3688.
  • 5Rosen JB,Thomas AR,Lexau CA,et al.Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States[J].Clin Infect Dis,2011,53(2):137-143.
  • 6Arguedas A,Dagan R,Guevara S,et al.Middle ear fluid Streptococcus pneumoniae serotype distribution in Costa Rican children with otitis media[J].Pediatr Infect Dis J,2005,24(7):631-634.
  • 7Leach AJ,Morris PS,McCallum GB,et al.Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001[J].BMC Infect Dis,2009,9:121.
  • 8Dinleyic EC,Yargic ZA.Pneumococcal conjugate vaccine:PHiDCV[J].Expert Rev Anti Infect Ther,2009,7(9):1063-1074.
  • 9Poolman JT,Frasch CE,K(a)yhty H,et al.Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines[J].Clin Vaccine Immunol,2010,17(1):134-142.
  • 10Silfverdal SA,Skerlikova H,Zanova M,et al.Anamnestic immune response in 3-to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life[J].Pediatr Infect Dis J,2011,30(9):e155-163.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部